Trial
NCT06599502
A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
—
Condition
Advanced Solid Tumours
Intervention
AZD0022
Why stopped
The decision to cease enrolment and proceed with the early termination of the ALAFOSS 01 (D7080C00001) study was based on strategic company portfolio prioritization.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-18